Clinical studies

Recent Articles

RELATED ARTICLES

  1. The biotech company has been dogged by multiple challenges recently, including declining revenue, ongoing losses and a recent rejection by one of its overseas partners.
    Junshi hopes new scientist CEO can cure its woes
    1877.HK 688180.SHG
  2. Junshi narrows its losses but delivers no cure for share price woes
    1877.HK 688180.SHG
  3. Akeso marks profit milestone with swift rights issue
    9926.HK
  4. Test results for new cancer drug take Akeso investors on wild ride
    9926.HK
  5. Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
    1952.HK
  6. BeiGene still bleeding red ink despite blockbuster drug
    BGNE.US 6160.HK 688235.SHG
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva